Athira Pharma Inc expected to post a loss of 63 cents a share - Earnings Preview

LeonaBio

04/11/2022 11:23

* Athira Pharma Inc  ATHA.OQ   ATHA.O  is expected to show
no
change in quarterly revenue when it reports  results on November
8 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Athira Pharma Inc
is for
a loss of 63 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Athira
Pharma Inc
is $5.5​, above​ its last closing price of $3.05. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.64       -0.64      -0.65     Missed  -1.8
 Mar. 31 2022  -0.53       -0.55      -0.56     Missed  -1.8
 Dec. 31 2021  -0.44       -0.54      -0.45     Beat    16.7​
 Sep. 30 2021  -0.50       -0.50      -0.42     Beat    15.4
 ​​Jun.        -0.38       -0.34      -0.38     Missed  -10.1
 30 2021                                                
 Mar. 31 2021  -0.30       -0.30      -0.25     Beat    17.4​
 Dec. 31 2020              -0.40      -0.24     Beat    39.5
 Sep. 30 2020  -0.25       -0.25      -1.12     Missed  -348
 This summary was machine generated November 4 at 11:23 GMT.  All
figures in US dollars  unless otherwise stated